Challenges And Opportunities For Quantitative Clinical Pharmacology In Cancer Immunotherapy: Something Old, Something New, Something Borrowed, And Something Blue
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY(2015)
Abstract
Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has matured during this time, application to CIT may not be straightforward since CIT acts via the immune system. Here we discuss where qCP approaches might best borrow or start anew for CIT.
MoreTranslated text
Key words
cancer,clinical pharmacology
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined